(Total Views: 141)
Posted On: 12/13/2021 8:55:51 AM
Post# of 89165
$APRE News Article - Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting https://marketwirenews.com/news-releases/apre...59779.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
